Bharat Biotech's nasal Covid vaccine gets approval

9 Sep 2022 , 12:41 PM

India now has access to the most recent immunization method, which has been hailed as a game-changer in the treatment of the disease, with the introduction of Bharat Biotech’s nasal vaccine against Covid-19.

The Indian pharma regulator has given the nasal vaccine made by Bharat Biotech, known as iNCOVACC, permission for “Restricted Use in Emergency Situation” in those 18 years of age and older. Nasal drops can be used to deliver intranasally using iNCOVACC, which has been specially formulated to do so. According to the Hyderabad-based company, the nasal delivery device has been built to be affordable in low- and middle-income nations.

The World Health Organization (WHO) stated last month that the current generation of vaccinations was created with the intention of preventing serious illness and death and that they have been successful in doing so, saving millions of lives. They haven’t, however, significantly lessened transmission. New and hazardous strains of the virus are developing as it spreads extensively, some of which are reported to decrease the effectiveness of immunizations.

The nasal vaccine will be simple to administer, according to doctors, and a higher uptake is also anticipated.

Washington University St. Louis, which had created and developed the recombinant adenoviral vectored constructs and assessed their effectiveness in preclinical research, collaborated with Bharat Biotech to produce iNCOVACC. The Indian government provided funding for product development and clinical testing via the COVID Suraksha program of the Department of Biotechnology.

In order to assess iNCOVACC as a primary dosage schedule and as a heterologous booster dose (different from the first dose) for participants who have already received two doses of the two regularly used covid vaccines in India, clinical trials were done.

According to Bharat Biotech, iNCOVACC has the dual advantages of facilitating quicker development of variant-specific vaccines and easy nasal delivery that facilitates mass immunization to guard against worrying emerging variants.

For feedback and suggestions, write to us at [e-mail]